Published in Clin Exp Immunol on March 09, 2017
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol (2005) 6.27
Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol (2009) 5.27
PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med (2010) 4.74
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med (2013) 3.70
Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry (2006) 2.92
Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum (2007) 2.40
Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum (2005) 2.30
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med (2008) 2.17
A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline. Anal Biochem (2000) 2.15
Peptidylarginine deiminase 4 contributes to tumor necrosis factor α-induced inflammatory arthritis. Arthritis Rheumatol (2014) 2.14
The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum (2004) 2.12
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). J Biol Chem (1999) 1.93
Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature (2014) 1.81
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis (2005) 1.80
Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med (2010) 1.78
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry (2010) 1.66
Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res (2000) 1.61
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol (2015) 1.41
Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J Neurosci (2006) 1.41
Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol (2007) 1.39
Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol (2006) 1.38
The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol (2004) 1.38
Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells. Apoptosis (2006) 1.36
Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis (2014) 1.34
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med (2008) 1.34
Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther (2006) 1.32
Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem (2002) 1.31
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum (2000) 1.31
Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med (2011) 1.28
Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) (2006) 1.25
Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis (2006) 1.18
Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol (2009) 1.15
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation. Chembiochem (2010) 1.13
Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol (2011) 1.12
Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum (2003) 1.10
Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol (2011) 1.10
PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Ann Rheum Dis (2009) 1.06
PAD4 is not essential for disease in the K/BxN murine autoantibody-mediated model of arthritis. Arthritis Res Ther (2012) 1.06
Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum (2002) 1.02
Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. J Immunol (2006) 0.97
Complement activation and inhibition in experimental models of arthritis. Mol Immunol (2000) 0.95
Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol (2010) 0.94
PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Ann Rheum Dis (2010) 0.91
The developmental expression and activity of peptidylarginine deiminase in the mouse. Neurosci Lett (1999) 0.89
Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model. Sci Rep (2015) 0.88
The W620 Polymorphism in PTPN22 Disrupts Its Interaction With Peptidylarginine Deiminase Type 4 and Enhances Citrullination and NETosis. Arthritis Rheumatol (2015) 0.82
Protein Arginine Methylation and Citrullination in Epigenetic Regulation. ACS Chem Biol (2015) 0.81
Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice. BMC Musculoskelet Disord (2016) 0.80
Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. Sci Rep (2016) 0.79
Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation. Arthritis Res Ther (2016) 0.76
Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation. Eur J Immunol (2016) 0.76